Not legal advice. Not a scare piece. The actual legal status of every major peptide — compound by compound, country by country.
The 2025–2026 FDA enforcement wave targeted vendors, not users. Here is the current regulatory status of 17 major peptide compounds across the US, UK, and Australia.
Approved (Rx) — FDA/regulatory approved with a prescription pathway | Grey Market — Not approved but not explicitly banned; enforcement targets vendors | Banned / Scheduled — Explicitly prohibited or scheduled controlled substance
| Compound | United States | United Kingdom | Australia | Rx Path | User Risk |
|---|---|---|---|---|---|
| BPC-157 | Grey Market | Grey Market | Scheduled (S4) | No | LOW |
| TB-500 | Grey Market | Grey Market | Grey Market | No | LOW |
| Semaglutide | Approved (Rx) | Approved (Rx) | Approved (Rx) | Yes (Rx) | VERY HIGH |
| Tirzepatide | Approved (Rx) | Approved (Rx) | Approved (Rx) | Yes (Rx) | VERY HIGH |
| Retatrutide | Grey Market | Grey Market | Grey Market | No | MEDIUM |
| CJC-1295 | Grey Market | Grey Market | Grey Market | Limited | LOW |
| Ipamorelin | Grey Market | Grey Market | Grey Market | Limited | LOW |
| PT-141 | Approved (HSDD) | Grey Market | Grey Market | Yes (Rx) | LOW |
| Selank | Grey Market | Grey Market | Grey Market | No | LOW |
| Semax | Grey Market | Grey Market | Grey Market | No | LOW |
| Epithalon | Grey Market | Grey Market | Grey Market | No | LOW |
| GHK-Cu | Grey Market | Grey Market | Grey Market | No | LOW |
| AOD-9604 | Grey Market | Grey Market | TGA rejected | No | LOW-MEDIUM |
| MOTS-c | Grey Market | Grey Market | Grey Market | No | LOW |
| SS-31 | Grey Market | Grey Market | Grey Market | No | LOW |
| Thymosin Alpha-1 | Grey Market | Approved (some) | Grey Market | Limited | LOW |
| Dihexa | Grey Market | Grey Market | Grey Market | No | LOW |
The live page at tonygreenberg.com/whats-legal allows filtering by compound name, status, and country. The search field accepts any compound name or status keyword.